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Gail Vines
What links a champion woman
runner, a premier-league soccer team,
and a 53 year old male biochemist?
Citizens of Dundee, Scotland’s
fourth largest city, will know the
answer: all three are local heroes.
And no wonder biochemist Philip
Cohen is a local hero. Over the past
nearly 30 years, he has
played midwife to the
birth of a scientific
megapolis on the banks of
the River Tay. Today,
redundant shipyards and
jute factories have given
way to research
laboratories and technology
parks. Biomedical research
is now the city’s third
largest industry, and
growing. Already, it rivals
Oxford and Cambridge as a centre of
bioscientific excellence.
Explanations of the ‘Dundee
phenomenon’ vary, but generally
begin or end with Philip Cohen.
“He has turned a sleepy provincial
university into one of the best
biochemistry departments in the
country,” says one fellow
biochemist. “Most people start by
thinking Dundee is the last place
they’d want to work,” comments a
university colleague. “Then Philip
persuades them to come.”
His scientific reputation is part of
the lure. A pioneer in the study of
protein phosphorylation, he is now
“one of the top three people in the
world in the field of signal
transduction,” says one US-based
ex-student. Cohen is generally
thought to be smart but, what’s more,
he is arguably Britain’s most
accomplished scientific entrepreneur.
A Royal Society Research
Professor since 1984, he persuaded
the Medical Research Council to
fund a Protein Phosphorylation Unit
in Dundee in 1990. Two years ago,
he celebrated the opening of a new
laboratory, built with £10 million
from the Wellcome Trust along with
hefty contributions from other
benefactors, including the late
novelist Catherine Cookson and
film star Sean Connery. Recently, he
has won drug-company sponsorship
for a new Signal Transduction
Therapy division. Last year he 
was knighted.
Cohen arrived in Dundee in
1971, bearing a first-class degree and
a PhD from University College
London and fresh from a two-year
stint in Seattle with Edmond
Fischer, who later shared a Nobel
Prize for his discovery of the first
protein kinase. “People told me
Dundee was in the middle of
nowhere, but after my stint in the
States, distances didn’t bother me,”
Cohen says. After all, Seattle was
several hours from the nearest
research centre in San Francisco.
“All the same, I was naive. It never
occurred to me that Dundee hadn’t
the money to buy the equipment I
wanted.” But after a few lean years,
Cohen perfected the art of getting
grants, and is proud that he’s spent
only four years on the university
payroll.
Some fellow researchers find
him “impossibly arrogant on a
personal level — he always has to
have the last word on everything.”
Certainly if Cohen harbours self-
doubt, he has buried the tell-tale
signs more successfully than most.
But one former student predicted
that I would find him charming, and
so I did.
Yet former students say he is
demanding and prone to tantrums.
He is infamous for his ‘lab rules’,
which stipulate the hours a student
must work and forbid the reading of
newspapers on the premises.
Absences of more than 20 minutes
must be accounted for. Students
fresh from undergraduate freedoms
may bridle at such restrictions, but
one ex-student wryly comments that
although he thought the rules
“ridiculous when I started, now that
I’m starting my own lab they
actually seem quite reasonable.”
Cohen remains unrepentant.
“Research is a vocation; if they don’t
want to do it, they shouldn’t be
here,” he says. “I have a
responsibility to tell students what
they need to do to be successful.”
And everyone agrees that a lot of
very successful people have come
out of his laboratory over the past
couple of decades.
He certainly likes to win. “If I
do anything, I like to do it
competitively — otherwise it’s just
messing around.” A keen golfer with
a handicap of 13, he also plays
bridge and chess to a high standard.
His daughter, following her parents
into biomedical research as a
graduate student in immunology at
Oxford, is also Britain’s top young
bridge player on the international
circuit.
Yet the uncompetitive world of
natural history also intrigues Cohen,
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who likes to watch the birds and
seals on the estuary, or collect wild
mushrooms from the unspoilt
countryside near Dundee. The son
of a chemist who perfected the
printing ink technology for the
Sunday Times’ first colour magazine,
the young Cohen excelled in school
science but also spent long hours
bird-watching and pond dipping
around his home on the outskirts of
London. “Naively, I imagined that
biochemistry would be somewhere
in between.”
Today, he is an energetic, tireless
and very persuasive campaigner for
British biochemistry, colleagues say,
even encouraging students to publish
in British or European journals rather
than American ones. “Many of my
most cited papers have been
published in Current Biology, the
European Journal of Biochemistry and
FEBS Letters,” he notes. “Americans
are always looking for an excuse not
to read European journals. We are
cutting our own throats if we don’t
publish in them.”
Success has come through “hard
work, good luck and some intuition,”
Cohen says. These days, he reckons
his instant recall may be less sharp
than it was but his intuition is getting
better. He began to study protein
phosphorylation when it appeared to
be a mechanism linked only to
glycogen metabolism. “Now it seems
that protein phosphorylation
regulates everything.”
Cohen may have been lucky in
his early research directions but he
says he has also developed a gift for
spotting the unexpected. Five years
ago, “I had never done anything
with a pharmaceutical company,”
Cohen says. Now, long-term
industrial collaborations to generate
“huge batteries of specific kinase
and phosphatase inhibitors” are a
major goal, Cohen reckons. “This is
the way to solve cell signalling,” his
intuiton tells him, and some of the
pharmaceuticals giants are listening.
Gail Vines is a freelance science writer based
in Cambridge, UK.
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Zeneca
What is it famous for? At the moment,
for merging successfully with
Swedish drug makers Astra. By
joining forces with another mid-sized
pharmaceutical company, UK-based
Zeneca has leapfrogged to the
number one position in the league
table of pharmaceutical giants. The
combined company, called
AstraZeneca, has a 4.3% share of the
world’s US$251 billion prescription
drug market. The closest rivals
Merck, Glaxo Wellcome and Novartis
are all tied in second place, according
to 1998 sales figures.
How did Zeneca begin? Six years ago,
Zeneca was spun off from the drug
and agrochemical interests of the old
Imperial Chemical Industries (ICI).
Where is the new company based?
The corporate headquarters is in
London but research will be directed
from Sweden. Some 6,000 jobs are
expected to be lost over the next
three years, mainly in administration.
Why merge? Sir Richard Sykes, Glaxo
Wellcome’s chairman, summed it up
when he said that drug companies
come together “not to protect future
earnings growth but to increase
critical mass to outperform the
industry … the more money you can
put into research, the stronger the
company’s going to be.” AstraZeneca
has the second largest Research &
Development budget among the
drug companies, at US$1.9 billion,
behind both Glaxo Wellcome and
Merck, who are tied in first place.
What has Zeneca brought to the
partnership? A portfolio of cancer
drugs rivalled only by that of Bristol
Myers Squibb. Zeneca’s leading
oncology product, tamoxifen, is the
world’s most widely prescribed breast
cancer medication. Tamoxifen made
international headlines last year
when the US National Cancer
Institute announced — some said
prematurely (see Curr Biol 1998,
8:R328) — that the drug can halve
the risk of breast cancer in women
genetically predisposed to the
disease. But Zeneca isn’t just a
one-drug wonder. Each of the
following Zeneca products is the
world’s top seller in its category:
Diprivan, a general anesthetic;
Inderal, a β-blocker; and Zestril, used
to treat high blood pressure and heart
failure. Zeneca is also a top producer
of agrochemicals, a business it is
keeping in the merged company.
What about Astra’s medicine chest? Its
ulcer remedy, Losec, is the
best-selling prescription drug in the
world. Astra is also responsible for
Xylocaine, the most widely used
local anesthetic in the world.
Is this an equal partnership? Although
billed as a “merger of equals”,
Zeneca’s share price was stronger
than Astra’s at the time of the
merger. So Zeneca ends up as the
larger partner despite Astra’s drugs
business being of a similar size.
Who stands to gain? Merck. As part of
a divorce settlement that will end a
1982 joint venture between Astra
and Merck, AstraZeneca will pay
Merck US$1.7 billion up front, and a
minimum of US$4.7 billion in 2008.
Chiroscience (based in Cambridge,
UK) is also smiling. Zeneca has been
forced to give up rights to Chirocaine,
an anesthetic developed by
Chiroscience and under worldwide
licence to Zeneca, as its only direct
competition would be one developed
by Astra. AstraZeneca will have to
pay US$16 million to Chiroscience in
compensation, and still continue to
develop Chirocaine for commercial
launch this year.
Isn’t everybody doing it? As the names
of the major players reveal, the
pharmaceutical industry has a strong
tradition of mergers — now, even
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